Drug discovery for overcoming chronic kidney disease (CKD): Development of drugs on endothelial cell protection for overcoming CKD

Journal of Pharmacological Sciences

Volumn 109, Issue 1, 2009, Pages 14-19

  Ishizawa, Keisuke ^a   Yamaguchi, Kunihisa ^a   Horinouchi, Yuya ^a   Fukuhara, Yayoi ^a   Tajima, Soichiro ^a   Hamano, Shuichi ^a   Tomita, Shuhei ^a   Tsuchiya, Koichiro ^b   Tamaki, Toshiaki ^a  

^a Department of Pharmacology ^*  (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Antioxidative effect; Chronic kidney disease (CKD); Endothelial dysfunction; Nitrosonifedipine

Indexed keywords

ACETYLCHOLINE; CUMENE HYDROPEROXIDE; INTERCELLULAR ADHESION MOLECULE 1; LIPID; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; NIFEDIPINE DERIVATIVE; NITROSONIFEDIPINE; RADICAL; UNCLASSIFIED DRUG;

CELL PROTECTION; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CYTOTOXICITY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; HYPERTENSION; IN VITRO STUDY; KIDNEY DYSFUNCTION; NONHUMAN; PROTEIN URINE LEVEL; RENAL PROTECTION; SHORT SURVEY; VASCULAR RING; VASODILATATION;

EID: 58649097286     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08R08FM     Document Type: Short Survey

References (43)

1. Zoccali C. The endothelium as a target in renal diseases. J Nephrol. 2007;20:S39-S44.
2. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant.2008;23:959-965.
3. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364:849-857.
4. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, et al. Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res. 2004;27:449-456.
5. Shinoda E, Yui Y, Kodama K, Hirayama A, Nonogi H, Haze K, et al. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension. 2005;45:1153-1158.
6. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet. 1990;335: 1109-1113.
7. Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension. 2001;37:240-245.
8. Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther. 2000;292:606-609.
9. Hempel A, Lindschau C, Maasch C, Mahn M, Bychkov R, Noll T, et al. Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. Circulation. 1999;99:2523-2529.
10. Matsumori A, Nunokawa Y, Sasayama S. Nifedipine inhibits activation of transcription factor NF-kappaB. Life Sci. 2000;67:2655-2661.
11. Majeed IA, Murray WJ, Newton DW, Othman S, Al-Turk WA. Spectrophotometric study of the photodecomposition kinetics of nifedipine. J Pharm Pharmacol. 1987;39:1044-1046.
12. Fujii H, Berliner LJ. In vivo EPR evidence for free radical adducts of nifedipine. Magn Reson Med. 1999;42:691-694.
13. Hayase N, Inagaki S, Abiko Y. Effects of photodegradation products of nifedipine: the nitroso-derivative relaxes contractions of the rat aortic strip induced by norepinephrine and other agonists. J Pharmacol Exp Ther. 1995;275:813-821.
14. Yanez C, Lopez-Alarcon C, Camargo C, Valenzuela V, Squella JA, Nunez-Vergara LJ. Structural effects on the reactivity 1,4-dihydropyridines with alkylperoxyl radicals and ABTS radical cation. Bioorg Med Chem. 2004;12:2459-2468.
15. Yoshizumi M, Tsuchiya K, Suzaki Y, Kirima K, Kyaw M, Moon JH, et al. Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-1 signaling pathway. Biochem Biophys Res Commun. 2002;293:1458-1465.
16. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today. 1998;19:80-88.
17. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912-1916.
18. Griendling KK, FitzGerald GA. Oxidative stress and cardio -vascular injury: Part II: animal and human studies. Circulation. 2003;108:2034-2040.
19. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol. 1997;20:II-11-17.
20. Thorpe GW, Fong CS, Alic N, Higgins VJ, Dawes IW. Cells have distinct mechanisms to maintain protection against different reactive oxygen species: oxidative-stress-response genes. Proc Natl Acad Sci USA. 2004;101:6564-6569.
21. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73:457-467.
22. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev. 1990;70:427-451.
23. Yoshizumi M, Fujita Y, Izawa Y, Suzaki Y, Kyaw M, Ali N, et al. Ebselen inhibits tumor necrosis factor-alpha-induced c-Jun N- terminal kinase activation and adhesion molecule expression in endothelial cells. Exp Cell Res. 2004;292:1-10.
24. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76: 301-314.
25. Modur V, Zimmerman GA, Prescott SM, McIntyre TM. Endothelial cell inflammatory responses to tumor necrosis factor alpha. Ceramide-dependent and -independent mitogen-activated protein kinase cascades. J Biol Chem. 1996;271:13094-13102.
26. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007;100:158-173.
27. Ishizawa K, Izawa Y, Ito H, Miki C, Miyata K, Fujita Y, et al. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension. 2005;46:1046-1052.
28. Tummala PE, Chen XL, Medford RM. NF-kappa B independent suppression of endothelial vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 gene expression by inhibition of flavin binding proteins and superoxide production. J Mol Cell Cardiol. 2000;32:1499-1508.
29. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multi- faceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006;291:H985-H1002.
30. Yung LM, Leung FP, Yao X, Chen ZY, Huang Y. Reactive oxygen species in vascular wall. Cardiovasc Hematol Disord Drug Targets. 2006;6:1-19.
31. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109:III27-III32.
32. Chen PY, Gladish RD, Sanders PW. Vascular smooth muscle nitric oxide synthase anomalies in Dahl/Rapp salt-sensitive rats. Hypertension. 1998;31:918-924.
33. Kanematsu Y, Tsuchiya K, Ohnishi H, Motobayashi Y, Izawa Y, Ishihara M, et al. Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in Nomega-nitro-L-arginine methyl ester-treated rats. Hypertens Res. 2006;29:369-374.
34. Kung CF, Moreau P, Takase H, Luscher TF. L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil. Hypertension. 1995;26:744-751.
35. Henrion D, Dowell FJ, Levy BI, Michel JB. In vitro alteration of aortic vascular reactivity in hypertension induced by chronic NG-nitro-L-arginine methyl ester. Hypertension. 1996;28:361-366.
36. Lefer AM, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovasc Res. 1996;32:743-751.
37. Koyanagi M, Egashira K, Kitamoto S, Ni W, Shimokawa H, Takeya M, et al. Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. Circulation. 2000;102:2243-2248.
38. Luvara G, Pueyo ME, Philippe M, Mandet C, Savoie F, Henrion D, et al. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol. 1998;18:1408-1416.
39. Kitamoto S, Egashira K, Kataoka C, Usui M, Koyanagi M, Takemoto M, et al. Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens. 2000;18:1795-1800.
40. Usui M, Egashira K, Tomita H, Koyanagi M, Katoh M,Shimokawa H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation. 2000; 101:305-310.
41. Chiu JJ, Wung BS, Shyy JY, Hsieh HJ, Wang DL. Reactive oxygen species are involved in shear stress-induced intercellular adhesion molecule-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:3570-3577.
42. Ying L, Flamant M, Vandermeersch S, Boffa JJ, Chatziantoniou C, Dussaule JC, et al. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats. Hypertension. 2003;42:937-944.
43. Kang DG, Sohn EJ, Lee YM, Lee AS, Han JH, Kim TY, et al. Effects of bulbus Fritillaria water extract on blood pressure and renal functions in the L-NAME-induced hypertensive rats. J Ethnopharmacol. 2004;91:51-56.